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Summary
BACKGROUND AND AIM: Hepatocellular carcinoma
(HCC) is the most frequent form of primary liver cancer
and chronic infection with hepatitis C virus is one of the
main risk factors for HCC. This study analyses the charac-
teristics of the patients with chronic hepatitis C participat-
ing in the Swiss Hepatitis C Cohort Study who developed
HCC.
METHODS: Analysis of the database of the Swiss Hepat-
itis C Cohort Study, a multicentre study that is being car-
ried out in eight major Swiss hospitals since the year 2000.
Patients with chronic hepatitis C and HCC were regrouped
and compared to the patients without HCC.
RESULTS: Among the 3,390 patients of the cohort, 130
developed an HCC. Age was one of the determining
factors. Cirrhosis and its complications ascites and porto-
systemic encephalopathy were associated with HCC.
Males presented a higher risk for HCC than females. Alco-
hol consumption was associated with HCC. Diabetes mel-
litus was an important risk factor, especially in patients
with low fibrosis. Patients with Hepatitis C genotype 2 had
significantly less HCC than patients with other genotypes.
A low socioeconomic status (income, education, profes-
sion) was associated with HCC.
CONCLUSIONS: Beside the expected characteristics (age,
gender, cirrhosis, alcohol), these data stress the role of dia-
betes mellitus and reveal the importance of low socioeco-
nomic status as a risk factor for HCC in Swiss patients in-
fected with hepatitis C virus. This vulnerable population
should be closely monitored.
Key words: hepatitis C virus; hepatocellular carcinoma;
risk factors; socioeconomic
Introduction
Hepatocellular carcinoma (HCC) is the most frequent form
of primary liver cancer. It is the fifth most common cancer
worldwide and the third cause of cancer mortality [1]. In
Europe, Oceania, Japan and America, chronic hepatitis C is
one of the main risk factors for HCC [2]. The virus has pos-
sible oncogenic properties, but many factors determining
the risk of developing an HCC are host dependent, some
are genetic and not modifiable, other are linked to lifestyle
and can be influenced. Lifestyle factors such as alcohol in-
take, cigarette smoking, and underlying diseases such as
obesity, diabetes and hepatitis B (HBV) and HIV co-infec-
tion have been reported to increase the risk for HCC [3].
Socioeconomic factors have also been found to influen-
ce this risk [4]. Few databases are comprehensive enough
and have a long enough follow-up to address prospectively
these factors. The Swiss Hepatitis C Cohort Study (SCCS)
established in 2000 with more than 3,000 participants of-
fers a unique setup to investigate these co-factors. The aim
of this study was to identify important co-factors influen-
cing the development of HCC in chronic Hepatitis C pa-
tients included in the SCCS.
Methods
Setting
The SCCS is a multicentre study started in September 2000
and is being carried out at eight major Swiss hospitals,
including 5 university hospitals (Basel, Bern, Geneva,
Lausanne and Zürich) and 3 major cantonal hospitals
(Lugano, Neuchâtel and St. Gallen). The SCCS collects
standardised prospective information on adults with hepat-
itis C virus (HCV) infection through questionnaires, clin-
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ical examination and laboratory investigations [5]. All the
enrolled patients signed an informed consent and the SCCS
protocol has been approved in each participating centre by
the local ethical committee. The database includes demo-
graphic information such as gender, age, social and edu-
cational background, occupational situation, household in-
come as well as co-morbidities, current and previous al-
cohol consumption and substance abuse. Histological in-
formation obtained by liver biopsy and results of laboratory
tests are also prospectively collected. Standardised follow-
up questionnaires cover events and behaviours since the
last visit. A ‘Stop Form’ is filled out when the patient is
either lost to follow-up or has died. The cause of death
is coded according to the ICD10 classification. To analyse
the database, patients were divided into 2 groups: the first
group includes all the patients with confirmed HCC and the
second group contains all the patients with no evidence for
HCC.
Inclusion criteria
The HCC group included all the patients who either had a
confirmed HCC at the time of recruitment or at any point
during the follow up period. All patients who had C22.0,
the ICD10 code for HCC, entered as cause of death were
also considered. The inclusion criteria were exclusively
based on the information of the SCCS database. For the
non-HCC group, all patients who had no evidence for HCC
were included. A downside of this approach is that for the
30 patients diagnosed with HCC before recruitment some
of the analysed factors cannot be considered as risk factors
leading to HCC. However, this approach can be justified
by the fact that most of the reviewed patient characteristics,
especially the ones that this study focused on do not change
with the cancer diagnosis.
Analysed factors
Demographic parameters at registration into the cohort
such as age, gender, education, occupational situation, in-
come were analysed. The following risk factors were ana-
lysed: alcohol consumption, intravenous drug abuse, in-
tranasal cocaine abuse, drug substitution, blood transfu-
sion, organ transplantation, invasive medical procedure,
profession with exposure to human blood, living in a
household with a HCV positive person, tattoos and pier-
cings. Clinical information included body mass index
(BMI), diabetes mellitus, gastrointestinal haemorrhage,
jaundice, ascites, porto-systemic encephalopathy. Laborat-
ory results comprised anti-HBc serology, HCV genotype,
hepatitis A (HAV) vaccination. Histological results such
as degree of fibrosis, grade of activity and steatosis were
available for patients who had a biopsy. For cirrhotic pa-
tients, the Child-Pugh score was used.
Definition of age
The patient’s age has been defined as follows:
For HCC patients the age for the study was set to the age
at the time of the cancer diagnosis. For the non-HCC group
age was calculated for the time of recruitment.
Statistical methods
In a first step, univariate analyses were performed on all
the evaluated co-factors. A Pearson-χ2 test was used to as-
sess the statistical significance of differences in the dis-
tributions of categorical variables between subjects in the
HCC and the non-HCC group. A p-value of <0.05 has been
considered statistically significant. Odds ratios (OR) with
corresponding 95% confidence intervals (95% CI) were
calculated with logistic regression analyses. To ensure bet-
ter independence of the different factors, all the analyses
were adjusted for gender and age. These two variables were
chosen for adjustment based on their well-known influence
on HCC development.
In a second step, binary multivariate logistic regressions
have been performed for each table. Due to the quantity
of analysed factors and number of missing values in some
variables it was not possible to run a multivariate analysis
including all discussed co-factors. For each factor in the
same table the overall statistical significance of the factor
was calculated along with the specific p-value and odds ra-
tio for each level of each factor against the first reference
level of that factor.
As a third analysis step, a hierarchical tree of risk factors
was calculated based on the top six most influential factors
(based on significance level and odds ratios), found in the
logistic regression. This analysis was conducted in order
to examine how these factors influence one another, and
whether they show any particularly interesting interactions
which could be used for diagnostic purposes.
Results
Information was available for 3,390 patients; the non-HCC
group included 3,260 patients and the HCC group 130 pa-
tients. The age profile was different between the 2 groups.
This is illustrated in the (fig. 1). The age categories 50–59,
60–69, 70–79 and 80–89 years were more represented in
the HCC group than in the non-HCC group. Reciprocally,
patients 20 to 49 year-old were less frequent in the HCC
group. The (fig. 2) is a box and whiskers plot comparing
the age in both groups. Mean age for the HCC group was
54 with a standard deviation of 12 years and a 95% CI of
52–56. Mean age for non-HCC group was 44 with a stand-
ard deviation of 11 and a 95% CI of 43–44. Median age for
the HCC group was 55 years and for the non-HCC group
42 years.
Figure 1
Age distribution in non-HCC and HCC group.
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The co-factors that were significant in the univariate ana-
lysis are listed in the table 1. Results of the multivariate
analysis were included where they were significant. Male
gender is an important risk factor. With an odds ratio of
1.70 (95% CI 1.14–2.53) males had a higher risk for HCC
compared to females. The multivariate analysis showed a
p-value of 0.032 and OR of 1.639, identifying male gender
as an independent risk factor. Fifty percent of the HCC
patients used to drink more than 20g of alcohol per day,
whereas 45% of the non-HCC patients were drinking reg-
ularly. This resulted in a gender and age adjusted OR of
1.55 (95% CI 1.06–2.27) with alcohol as a co-factor. Liver
cirrhosis was strongly associated with HCC. It was differ-
ently distributed among the 2 groups: 66% of the HCC pa-
tients had cirrhosis, whereas only 21% of the non-HCC pa-
tients, this calculated an OR of 4.82 (95% CI 3.28–7.09).
Patients with a Child Pugh classification B or C had an in-
creased HCC risk compared to patients with a Child Pugh
classification A. Patients with Child Pugh classification C
did not have greater HCC risk than patients with Child
Pugh classification B. Clinical consequences of cirrhosis
such as ascites (p<0.001, OR 3.86, 95%CI 2.34–6.37) and
porto-systemic encephalopathy (p = 0.009, OR 3.46 95%CI
1.36–8.78) were significantly associated with HCC,
gastrointestinal haemorrhage was close to significant (p =
0.084, OR 1.85, 95% CI 0.92–3.70). In the SCCS database,
test results for HBc-antibodies can be either negative, pos-
Figure 2
Box and whiskers plot of age for non-HCC and HCC group.
Figure 3
Frequency hepatitis C virus genotypes, compared between HCC
and non-HCC group.
itive or borderline. Borderline test results showed a signi-
ficantly higher risk for HCC than both positive and negat-
ive anti-HBc (p <0.001, OR = 2.96 95%CI 1.65–5.32). In
the multivariate analysis this co-factor stood out with an
overall p-value of 0.018 and p = 0.013 for anti-HBc border-
line. Merging borderline and positive test results into one
group diminished this effect: p = 0.063, OR = 1.44, 95%CI
0.98–2.10 (results not in table). At last, patients with dia-
betes mellitus had higher risk for HCC (p = 0.002, OR 2.08,
95%CI 1.30–3.34).
The table 2 describes the effects of histological findings
based on a univariate and multivariate analysis. Neither the
activity nor the presence of steatosis showed evidence for
an increased risk of HCC. In contrast, increased fibrosis
stage was associated with HCC. Patients with histological
probable or definite cirrhosis had a much higher cancer risk
compared to those with no histological fibrosis (p = 0.007,
OR 5.15, 95% CI 1.56–6.98). The multivariate p-value of
<0.001 confirmed fibrosis as an independent factor in this
table.
The socioeconomic factors are detailed in the table 3. There
seems to be an inverse association between HCC and an-
nual income. The HCC risk increased as the income de-
creased. Taking the lowest income category as a reference
our results revealed higher incomes as protective factors.
Patients with an annual income of >80 000 Swiss francs
had a smaller risk of developing HCC than patients with
an income of <40 000; however, this association did not
reach statistical significance (p = 0.056, OR 0.57, 95%CI
0.32–1.02). Patients with higher education had a smaller
risk for HCC than patients with no education, this asso-
ciation was significant (p=0.027 OR = 0.54, 95%CI
0.31–0.93). A comparison of the patient’s profession
showed no significant differences. All three factors were
non-significant in the multivariate analysis.
The distribution of patients with HCC among the different
HCV genotypes is shown in the (fig. 3. Genotype 1 was the
most common and it was slightly more frequent in HCC pa-
tients than in the non-HCC group. The risk analysis for the
HCV genotypes is provided in table 4. It revealed a smaller
HCC risk for patients with genotype 2.
Finally, in order to better understand the place of the dif-
ferent factors, a hierarchical tree was generated based on
the six most important risk factors (gender, age, diabetes,
fibrosis, antiHBc, income). On each level, the box furthest
to the right is the factor with the highest risk for HCC. The
tree identified age as the main risk factor. The age groups
<42, 42–60, >60 were automatically selected as the best
ones to distinguish between HCC and non-HCC patients.
The younger patient group was further subcategorised de-
pending on the antiHBc test result. Borderline antiHBc ap-
peared to be a relevant risk factor. In the middle aged group
(42–60) it was observed, that diabetes mellitus is an im-
portant risk factor for patients with low histological fibrosis
level. In patients over 60, cirrhosis was the most important
risk factor for HCC.
Discussion
There are a number of co-factors influencing the develop-
ment of HCC in patients with chronic hepatitis C. In the
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SCCS we identified male gender, cirrhosis, alcohol intake,
diabetes and lack of education as being significantly asso-
ciated with HCC.
We found a different age distribution with non-HCC pa-
tients being much younger than HCC patients. There was
an increased risk after the age of 42 and a further increase
in risk after 60. This is consistent with data on 2166 chronic
hepatitis C patients which reported a 15-fold higher risk for
HCC in patients over 65 years of age compared to patients
in their 20’s [6]. The age peak in our study was between 60
and 69 years. A US study showed an age peak in patients
aged 70–74 years for the years 2000 to 2002 [3]. They
reported a substantial shift towards younger age with the
maximum age being 75–79 in 1991–1993 and 80–84 years
in 1982–1984. Our age peak was in line with this trend to-
wards younger age over time.
In almost every study, HCC is reported to be more frequent
in male than in female patients. Our analysis identified
male gender as an independent risk factor. It showed a male
to female ratio of 2.7:1. This ratio is rather low ratio since
other studies reported a male to female ratio up to 5:1 [3].
Several reasons may explain this male predominance. First,
men likely expose themselves to more risk factors. They
generally drink more alcohol. Second, there are biological
factors [7]. A study with telomerase-deficient mice showed
that male mice had a 2 to 8-fold higher risk for HCC than
female mice [8]. This implies that male gender hormones
may favour liver cancer development. Mice lacking an-
drogen receptor present delayed development of HCC [9].
The unfavourable effect of androgens can be further under-
lined by a study from Taiwan that associated elevated ser-
um testosterone levels with the development of HCC [10].
In our cohort, alcohol consumption was more frequent in
patients with HCC (50%) than in patients without HCC
(45%). Age and gender adjusted OR of 1.55 (95%CI
1.06–2.27) with a p-value of under 0.05 suggested that al-
cohol is a risk factor for HCC in HCV patients. This is in
line with the published evidence. A European study repor-
Table 1: Highly associated co-factors.
HCC, N (%) Non-HCC, N (%) Univariate pa OR (95% CI)b Multivariate pc Multivariate ORd
Gender
Total 130 (100) 3,260 (100)
Male 96 (73.85) 2,036 (62.45) 0.009 1.70 (1.14–2.53) 0.032 1.639
Female 34 (26.15) 1,224 (37.55) Reference Reference
Drinker (>20g/d)
Total 129 (100) 3,257 (100) nse
No 64 (49.61) 1,802 (55.33) Reference
Yes 65 (50.39) 1,455 (44.67) 0.024 1.55 (1.06–2.27)
Cirrhosis
Total 130 (100) 3,256 (100) ns
No 44 (33.85) 2,586 (79.42) Reference
Yes 86 (66.15) 670 (20.58) <0.001 4.82 (3.28–7.09)
Child Pugh
Total 86 (100) 670 (100) ns
A (5–6) 54 (62.79) 494 (73.73) Reference
B (7–10) 28 (32.56) 145 (21.64) 0.041 1.73 (1.02–2.91)
C (11–15) 4 (4.65) 31 (4.63) 0.369 1.67 (0.54–5.16)
Ascites
Total 130 (100) 3,260 (100) ns
No 106 (81.54) 3,136 (96.20) Reference
Yes 24 (18.46) 124 (3.80) <0.001 3.86 (2.34–6.37)
Porto-systemic encephalopathy
Total 130 (100) 3,260 (100) ns
No 124 (95.38) 3,226 (98.96) Reference
Yes 6 (4.62) 34 (1.04) 0.009 3.46 (1.36–8.78)
Gastrointestinal haemorrhage
Total 130 (100) 3,260 (100) ns
No 120 (92.31) 3,160 (96.93) Reference
Yes 10 (7.69) 100 (3.07) 0.084 1.85 (0.92–3.70)
Anti-HBc
Total 122 (100) 2,986 (100) 0.018
Negative 62 (50.81) 1,645 (55.09) Reference 0.74 0.93
Borderline 17 (13.93) 158 (5.29) <0.001 2.96 (1.65–5.32) 0.013 2.245
Positive 43 (35.24) 1,183 (39.61) 0.432 1.18 (0.78–1.78) Reference Reference
Diabetes
Total 130 (100) 3,247 (100) ns
No 103 (79.23) 3,051 (93.96) Reference
Yes 27 (20.77) 196 (6.04) 0.002 2.08 (1.30-3.34)
Abbreviations: HCC = patients with hepatocellular carcinoma; OR = odds ratio, 95% CI = 95% confidence interval; ns = not significant; ap-value for univariate analysis,
adjusted for gender and age; bodds ratio for univariate analysis adjusted for gender and age; cp-value for multivariate analysis of whole table; dodds ratio for multivariate
analysis of whole table.
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ted that alcohol consumption of over 11 litres per year in-
creased the risk of liver cancer by 26% in men and 14% in
women [11]. Donato et al. reported that HCC risk increases
linearly with alcohol consumption [12].
Hepatic fibrosis is a key risk factor for HCC. We found the
risk for HCC to increase up to an OR of 5.15 with increas-
ing stadium of fibrosis. This is corroborated by the find-
ing that cirrhosis was associated with an OR of 4.82. Res-
ults from other studies have already proven cirrhosis to be
the main risk factor for HCC in hepatitis C patients [2].
Among the hepatitis C patients with cirrhosis the annual
incidence of HCC is 1.4% in the USA, 2–4% in Italy and
4–8% in Japan [2]. Cirrhosis does not only influence the
incidence of primary liver cancer but seems to also influ-
Table 2: Histological factors
HCC, N (%) Non-HCC, N (%) Univariate pa OR (95% CI)b Multivariate pc Multivariate ORd
Activity of chronic hepatitis
Total 101 (100) 1,921 (100) 0.228
A0 (none) 4 (3.96) 38 (1.98) Reference
A1 (minimal) 19 (18.81) 652 (33.94) 0.031 0.27 (0.08 –0.89) 0.020 0.19
A2 (mild) 38 (37.62) 799 (41.59) 0.113 0.40 (0.13–1.24) 0.035 0.23
A3 (moderate) 34 (33.66) 389 (20.25) 0.264 0.52 (0.16–1.64) 0.049 0.24
A4 (severe) 6 (5.94) 43 (2.24) 0.497 0.61 (0.15–2.53) 0.066 0.20
Fibrosis
Total 102 (100) 1,931 (100) <0.001
None 3 (2.94) 195 (10.10) Reference
Portal fibrosis 9 (8.82) 567 (29.36) 0.894 0.91 (0.24–3.45) 0.825 1.21
Portal fibrosis with rare septa 21 (20.59) 550 (28.48) 0.37 1.76 (0.51–6.05) 0.169 2.98
Bridging fibrosis 10 (9.80) 241 (12.48) 0.52 1.54 (0.41–5.79) 0.165 3.20
Probable or definite cirrhosis 59 (57.84) 378 (19.58) 0.007 5.15 (1.56–6.98) 0.004 9.50
Steatosis
Total 90 (100) 1,905 (100)
No 21 (23.33) 548 (28.77) Reference
Yes 69 (76.67) 1,357 (21.23) 0.577 0.86 (0.51–1.45) 0.266 0.732
Abbreviations: HCC = patients with hepatocellular carcinoma; OR = odds ratio, 95% CI = 95% confidence interval; ns = not significant; ap-value for univariate analysis,
adjusted for gender and age; bodds ratio for univariate analysis adjusted for gender and age; cp-value for multivariate analysis of whole table; dodds ratio for multivariate
analysis of whole table.
Note that not all patients did have a liver biopsy available.
Table 3: Socioeconomic factors.
HCC, N (%) Non-HCC, N (%) Univariate pa OR (95% CI)b multivariate pc multivariate ORd
Annual Income in Swiss Francs
Total 98 (100) 2,528 (100) 0.202
<40,000 38 (38.78) 1,051 (41.57) Reference Reference
40,000–80,000 40 (40.82) 930 (36.79) 0.305 0.78 (0.48–1.25) 0.080 1.925
>80,000 20 (20.40) 547 (21.64) 0.056 0.57 (0.32–1.02) 0.145 1.599
Education
Total 128 (100) 3,222 (100) 0.225
No education 32 (25.00) 709 (22.00) Reference Reference
Short-time professional education 11 (8.59) 385 (11.95) 0.081 0.53 (0.26–1.08) 0.935 0.97
Finished apprenticeship 59 (46.09) 1,455 (45.16) 0.306 0.79 (0.50–1.24) 0.161 0.473
Higher education (bachelor-university) 26 (20.31) 673 (20.88) 0.027 0.54 (0.31–0.93) 0.436 1.264
Profession
Total 127 (100) 3,210 (100) 0.543
Unemployed 8 (6.29) 351 (10.93) Reference Reference
Employed 62 (48.82) 2047 (63.77) 0.924 0.96 (0.45–2.05) 0.454 1.351
Retired 57 (44.88) 812 (25.29) 0.57 1.26 (0.57–2.80) 0.291 1.37
Abbreviations: HCC = patients with hepatocellular carcinoma; OR = odds ratio, 95% CI = 95% confidence interval; ns = not significant; ap-value for univariate analysis,
adjusted for gender and age; bodds ratio for univariate analysis adjusted for gender and age; cp-value for multivariate analysis of whole table; dodds ratio for multivariate
analysis of the whole table.
Table 4: Risk analysis for HCV genotypes.
HCC, N (%) Non-HCC, N (%) Univariate pa ORa (95%CI)
HCV genotype
Total 118 (100) 3,075 (100)
Genotype 1 73 (61.86) 1574 (51.19) 0.005 2.78 (1.37–5.65)
Genotype 2 10 (8.47) 271 (8.81) Reference
Genotype 3 26 (22.03) 917 (29.82) 0.009 2.97 (1.31–6.72)
Genotype 4 9 (7.63) 313 (10.17) 0.052 2.61 (0.99–6.89)
a Adjusted for gender and age.
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ence its severity. A study with North American patients re-
ported that patients with liver cirrhosis develop more ag-
gressive and less differentiated HCC than patients without
cirrhosis [13]. In contrast, neither histological activity of
chronic hepatitis C, nor steatosis were associated with the
development of HCC in the SCCS.
Our results showed that patients with Child-Pugh class B
had higher risk for HCC than those with Child-Pugh class
A. This is not surprising and fits with data about the histo-
logical degree of fibrosis and the increased risk for HCC in
patients with ascites and in patients with porto-systemic en-
cephalopathy. However, it is less obvious why patients with
Child Pugh class C do not have a higher HCC risk than pa-
tients with Child Pugh class B. One explanation might be
that patients with Child Pugh class C have a short survival
and when they reach this stage without HCC they die from
liver failure and/or complications of portal hypertension.
A recent meta-analysis of 59 studies came to the conclusion
that HBV/HCV co-infection does not increase the risk of
HCC compared to HBV or HCV mono-infection [14]. Our
analysis showed a significant difference between border-
line anti-HBc test results to negative as well as positive test
results. Both the univariate and multivariate analysis sug-
gested that a borderline anti-HBc test result is an independ-
ent risk factor and based on the result of the hierarchical
tree the importance is limited to patients under 42 years of
age. These patients with borderline anti-HBc serology may
be in a particularly oncogenic stage of occult hepatitis B in-
fection.
In our results, 21% of the HCC patients and only 6% of
the non-HCC patients were diabetics (OR 2.08, 95% CI:
1.30–3–34, p = 0.002). We identified diabetes mellitus as
a strong risk factor for HCC in hepatitis C patients. This
is a well-known association in North America [15–17] as
well as in Europe [18–20]. Our results also suggested that
diabetes the determining factor in middle aged patients
(42–60) with low fibrosis stage. This concurs with recent
Figure 4
Hierarchial tree of important risk factors. Data for each level (left out
of graph to conserve comprehensibility): level 1 (hcc/non-hcc):
nonhcc = 96.2% (3,260), hcc = 3.8% (130); level 2 (age<42): non-
hcc = 98.9% (1,639), hcc = 1.1% (19); level 2 (age 42–60): non-hcc
= 95.5% (1,337), hcc = 4.5% (63); level 2 (age>60): non-hcc =
85.5% (284), hcc = 14.5% (48); level 3 (anti-HBcpos/neg): non-hcc
= 99.1% (1,570), hcc = 0.9% (14); level 3 (anti-HBc borderline):
non-hcc = 93.2% (69), hcc = 6.8% (5); level 3(fibrosis: none.): non-
hcc = 96.9% (1,099), hcc = 3.1% (35), level 3 (cirrhosis):non-hcc =
89.5% (238), hcc = 10.5% (28), level3 (fibrosis: none) non-hcc =
92% (231), hcc = 8% (20); level 3(cirrhosis): non-hcc = 65.4% (53),
hcc = 34.6% (28); level 4 (no diabetes): non-hcc = 97.3% (1,016),
hcc = 2.7% (28), level 4 (diabetes): non-hcc = 92.2% (83), hcc =
7.8% (7).
findings of HCC in diabetic patients without significant
fibrosis. [21]
One unique aspect of this work was to investigate the so-
cioeconomic characteristics of Swiss hepatitis C patients
who develop HCC. Our study took into account 3 socioeco-
nomic factors: professional occupation, education level and
annual income. We found no significant difference between
employed and unemployed patients. Compared to patients
with no education, patients with higher education had a
lower risk (OR 0.5) for HCC. The largest differences of
HCC risk was seen when comparing the patients’ annual
income. The HCC risk increased as the income decreased.
This is in line with the results of a study performed in
Korea that compared patients with low income (<4000
USD/month) to patients with high income (>4000 USD/
month). They found an odds ratio of 17 (95% CI
4.27–68.25), linking low income to higher HCC incidents
[4]. We found no difference between the three factors in
the multivariate analysis, which is mainly because the three
groups are very similar. Patients with higher education gen-
erally have better jobs and earn more than patients with
no education. Our conclusion is that patients with low so-
cioeconomic status have a higher risk for HCC. A possible
explanation may be that patients with little education and
low income present additional co-factors [22]. Another
possibility is that these patients do not seek medical at-
tention and thereby are less likely to be treated. So far, in
Switzerland, the socioeconomic status has no influence on
treatment decisions [23]. Based on these results, however,
patients with low income and education should be more
closely monitored.
Genotype 1 is the most frequent genotype in the SCCS and
patients with HCC slightly more frequently harbour this
genotype. A meta-analysis came to the conclusion that pa-
tients with genotype 1b have an almost 2-fold (OR1.78,
95%CI 1.36–2.32) risk of developing HCC than those with
other genotypes [24]. Our risk analysis showed that pa-
tients with genotype 2 had significantly less HCC risk than
patients with genotype 1.
This work has limitations. It is descriptive by nature and
does not provide mechanistic insights. It relies exclusively
on the data of the SCCS database. The charts of the patients
have not been reviewed and some important factors such as
smoking are missing. Moreover, the effect of the antiviral
therapy on the risk of developing HCC could not be eval-
uated. Nevertheless, this project has strengths. It is based
on a very large database and provides unique information
on Swiss patients infected with HCV who developed HCC.
This information should help improving the management
of these patients.
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Figures (large format)
Figure 1
Age distribution in non-HCC and HCC group
Figure 2
Box and whiskers plot of age for non-HCC and HCC group
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Figure 3
Frequency hepatitis C virus genotypes, compared between HCC and non-HCC group.
Figure 4
Hierarchial tree of important risk factors. Data for each level (left out of graph to conserve comprehensibility): level 1 (hcc/non-hcc): nonhcc =
96.2% (3,260), hcc = 3.8% (130); level 2 (age<42): non-hcc = 98.9% (1,639), hcc = 1.1% (19); level 2 (age 42–60): non-hcc = 95.5% (1,337),
hcc = 4.5% (63); level 2 (age>60): non-hcc = 85.5% (284), hcc = 14.5% (48); level 3 (anti-HBcpos/neg): non-hcc = 99.1% (1,570), hcc = 0.9%
(14); level 3 (anti-HBc borderline): non-hcc = 93.2% (69), hcc = 6.8% (5); level 3(fibrosis: none.): non-hcc = 96.9% (1,099), hcc = 3.1% (35),
level 3 (cirrhosis):non-hcc = 89.5% (238), hcc = 10.5% (28), level3 (fibrosis: none) non-hcc = 92% (231), hcc = 8% (20); level 3(cirrhosis): non-
hcc = 65.4% (53), hcc = 34.6% (28); level 4 (no diabetes): non-hcc = 97.3% (1,016), hcc = 2.7% (28), level 4 (diabetes): non-hcc = 92.2% (83),
hcc = 7.8% (7)
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